We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
Read MoreHide Full Article
Concert Pharmaceuticals, Inc. shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Shares of Concert Pharma have outperformed the Zacks Classified Medical - Drugs industry so far this year. The company has gained 44.4% while the industry rose 4.9% in the period.
The FDA had previously approved the initiation of a phase IIa study on CTP-543, which began earlier this month. However, just before the start of patient dosing, the FDA yesterday informed Concert that the agency needs to review data from one recently completed non-clinical toxicology study. There was no safety concern cited by the FDA. However, agency clarified they intend to review this additional non-clinical data as support to one year dosage data from the planned phase IIa study.
With the FDA placing a clinical hold, new patient enrollment in the study has been halted for the time being. The company is actively working with the FDA to resume enrollment in the Phase IIa trial by submitting the requested non-clinical study reports as soon as possible. The FDA will notify Concert about the status of clinical hold within 30 days after the company’s response.
We note that Concert is developing CTP-543 for the treatment of alopecia areata, an autoimmune disease resulting in partial or complete loss of hair on the scalp and body. CTP-543 was discovered by applying its deuterium chemistry technology to modify Incyte Corporation’s (INCY - Free Report) oncology drug, Jakafi. Jakafi selectively inhibits Janus kinases 1 and 2, enzymes controlling signal transmission in cells and believed to be involved in this autoimmune disorder. Jakafi has been evaluated in academic settings and reported to promote hair growth in individuals suffering from moderate-to-severe alopecia areata.
We remind investors that Concert had inked a definitive deal with Vertex Pharmaceuticals Incorporated (VRTX - Free Report) in Mar 2017 to sell the worldwide development and commercialization rights of its cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Vivus’ loss per share estimates narrowed 22% to 39 cents for 2017 over the last 60 days. The company posted positive surprises in all the four trailing quarters with an average beat of 233.69%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
Concert Pharmaceuticals, Inc. shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Shares of Concert Pharma have outperformed the Zacks Classified Medical - Drugs industry so far this year. The company has gained 44.4% while the industry rose 4.9% in the period.
The FDA had previously approved the initiation of a phase IIa study on CTP-543, which began earlier this month. However, just before the start of patient dosing, the FDA yesterday informed Concert that the agency needs to review data from one recently completed non-clinical toxicology study. There was no safety concern cited by the FDA. However, agency clarified they intend to review this additional non-clinical data as support to one year dosage data from the planned phase IIa study.
With the FDA placing a clinical hold, new patient enrollment in the study has been halted for the time being. The company is actively working with the FDA to resume enrollment in the Phase IIa trial by submitting the requested non-clinical study reports as soon as possible. The FDA will notify Concert about the status of clinical hold within 30 days after the company’s response.
We note that Concert is developing CTP-543 for the treatment of alopecia areata, an autoimmune disease resulting in partial or complete loss of hair on the scalp and body. CTP-543 was discovered by applying its deuterium chemistry technology to modify Incyte Corporation’s (INCY - Free Report) oncology drug, Jakafi. Jakafi selectively inhibits Janus kinases 1 and 2, enzymes controlling signal transmission in cells and believed to be involved in this autoimmune disorder. Jakafi has been evaluated in academic settings and reported to promote hair growth in individuals suffering from moderate-to-severe alopecia areata.
We remind investors that Concert had inked a definitive deal with Vertex Pharmaceuticals Incorporated (VRTX - Free Report) in Mar 2017 to sell the worldwide development and commercialization rights of its cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Concert Pharmaceuticals, Inc. Price and Consensus
Concert Pharmaceuticals, Inc. Price and Consensus | Concert Pharmaceuticals, Inc. Quote
Zacks Rank & Key Pick
Concert Pharma currently has a Zacks Rank #4 (Sell). A better-ranked healthcare stock is VIVUS, Inc. . Vivus sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vivus’ loss per share estimates narrowed 22% to 39 cents for 2017 over the last 60 days. The company posted positive surprises in all the four trailing quarters with an average beat of 233.69%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>